The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on the viability and tumour development of breast cance...

Full description

Bibliographic Details
Main Authors: Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Anna Tankiewicz-Kwedlo, Beata Sieklucka, Krystyna Pawlak, Robert Czarnomysy, Krzysztof Bielawski, Arkadiusz Surazynski, Joanna Kalafut, Alicja Przybyszewska, Mariusz Koda, Katarzyna Jakubowska, Adolfo Rivero-Muller, Dariusz Pawlak
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
erythropoietin
lfm-a13
bruton’s tyrosine kinase
breast cancer
zebrafish
Online Access:http://dx.doi.org/10.1080/14756366.2020.1818738
id doaj-418377d1f791473ea76404dcb6f5a02c
record_format Article
spelling doaj-418377d1f791473ea76404dcb6f5a02c2021-07-15T13:10:33ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742020-01-013511697171110.1080/14756366.2020.18187381818738The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancerDariusz Rozkiewicz0Justyna Magdalena Hermanowicz1Anna Tankiewicz-Kwedlo2Beata Sieklucka3Krystyna Pawlak4Robert Czarnomysy5Krzysztof Bielawski6Arkadiusz Surazynski7Joanna Kalafut8Alicja Przybyszewska9Mariusz Koda10Katarzyna Jakubowska11Adolfo Rivero-Muller12Dariusz Pawlak13Department of Pharmacodynamics, Medical University of BialystokDepartment of Pharmacodynamics, Medical University of BialystokDepartment of Monitored Pharmacotherapy, Medical University of BialystokDepartment of Pharmacodynamics, Medical University of BialystokDepartment of Monitored Pharmacotherapy, Medical University of BialystokDepartment of Synthesis and Technology of Drugs, Medical University of BialystokDepartment of Synthesis and Technology of Drugs, Medical University of BialystokDepartment of Medicinal Chemistry, Medical University of BialystokDepartment of Biochemistry and Molecular Biology, Medical University of LublinDepartment of Biochemistry and Molecular Biology, Medical University of LublinDepartment of General Pathomorphology, Medical University of BialystokDepartment of Pathomorphology, Comprehensive Cancer CenterDepartment of Biochemistry and Molecular Biology, Medical University of LublinDepartment of Pharmacodynamics, Medical University of BialystokRecombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on the viability and tumour development of breast cancer cells. The results demonstrated that Epo significantly intensifies the anticancer activity of LFM-A13 in MCF-7 and MDA-MB-231. The featured therapeutic scheme efficiently blocked the tumour development in zebrafish experimental cancer model. Epo and LFM-A13 administered together resulted in effective cell killing, accompanied by attenuation of the BTK signalling pathways, loss of mitochondrial membrane potential (MMP), accumulation of apoptotic breast cancer cells with externalised PS, a slight increase in phase G0/G1 and a reduction in cyclin D1 expression. Simultaneous use of Epo with LFM-A13 inhibited early stages of tumour progression. This therapeutic scheme may be rationale for further possible research.http://dx.doi.org/10.1080/14756366.2020.1818738erythropoietinlfm-a13bruton’s tyrosine kinasebreast cancerzebrafish
collection DOAJ
language English
format Article
sources DOAJ
author Dariusz Rozkiewicz
Justyna Magdalena Hermanowicz
Anna Tankiewicz-Kwedlo
Beata Sieklucka
Krystyna Pawlak
Robert Czarnomysy
Krzysztof Bielawski
Arkadiusz Surazynski
Joanna Kalafut
Alicja Przybyszewska
Mariusz Koda
Katarzyna Jakubowska
Adolfo Rivero-Muller
Dariusz Pawlak
spellingShingle Dariusz Rozkiewicz
Justyna Magdalena Hermanowicz
Anna Tankiewicz-Kwedlo
Beata Sieklucka
Krystyna Pawlak
Robert Czarnomysy
Krzysztof Bielawski
Arkadiusz Surazynski
Joanna Kalafut
Alicja Przybyszewska
Mariusz Koda
Katarzyna Jakubowska
Adolfo Rivero-Muller
Dariusz Pawlak
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
Journal of Enzyme Inhibition and Medicinal Chemistry
erythropoietin
lfm-a13
bruton’s tyrosine kinase
breast cancer
zebrafish
author_facet Dariusz Rozkiewicz
Justyna Magdalena Hermanowicz
Anna Tankiewicz-Kwedlo
Beata Sieklucka
Krystyna Pawlak
Robert Czarnomysy
Krzysztof Bielawski
Arkadiusz Surazynski
Joanna Kalafut
Alicja Przybyszewska
Mariusz Koda
Katarzyna Jakubowska
Adolfo Rivero-Muller
Dariusz Pawlak
author_sort Dariusz Rozkiewicz
title The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
title_short The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
title_full The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
title_fullStr The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
title_full_unstemmed The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
title_sort intensification of anticancer activity of lfm-a13 by erythropoietin as a possible option for inhibition of breast cancer
publisher Taylor & Francis Group
series Journal of Enzyme Inhibition and Medicinal Chemistry
issn 1475-6366
1475-6374
publishDate 2020-01-01
description Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on the viability and tumour development of breast cancer cells. The results demonstrated that Epo significantly intensifies the anticancer activity of LFM-A13 in MCF-7 and MDA-MB-231. The featured therapeutic scheme efficiently blocked the tumour development in zebrafish experimental cancer model. Epo and LFM-A13 administered together resulted in effective cell killing, accompanied by attenuation of the BTK signalling pathways, loss of mitochondrial membrane potential (MMP), accumulation of apoptotic breast cancer cells with externalised PS, a slight increase in phase G0/G1 and a reduction in cyclin D1 expression. Simultaneous use of Epo with LFM-A13 inhibited early stages of tumour progression. This therapeutic scheme may be rationale for further possible research.
topic erythropoietin
lfm-a13
bruton’s tyrosine kinase
breast cancer
zebrafish
url http://dx.doi.org/10.1080/14756366.2020.1818738
work_keys_str_mv AT dariuszrozkiewicz theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT justynamagdalenahermanowicz theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT annatankiewiczkwedlo theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT beatasieklucka theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT krystynapawlak theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT robertczarnomysy theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT krzysztofbielawski theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT arkadiuszsurazynski theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT joannakalafut theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT alicjaprzybyszewska theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT mariuszkoda theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT katarzynajakubowska theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT adolforiveromuller theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT dariuszpawlak theintensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT dariuszrozkiewicz intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT justynamagdalenahermanowicz intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT annatankiewiczkwedlo intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT beatasieklucka intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT krystynapawlak intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT robertczarnomysy intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT krzysztofbielawski intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT arkadiuszsurazynski intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT joannakalafut intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT alicjaprzybyszewska intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT mariuszkoda intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT katarzynajakubowska intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT adolforiveromuller intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
AT dariuszpawlak intensificationofanticanceractivityoflfma13byerythropoietinasapossibleoptionforinhibitionofbreastcancer
_version_ 1721300910816100352

Similar Items